Oncology and Hematology: Archives

SUMMARY AND COMMENT

Novel Mutations in Myeloid Malignancies

• May 27, 2009
• Michael E. Williams, MD

TET2 gene mutations were common early events in patients with myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukemias.

• Reviewing:
• Delhommeau F et al., N Engl J Med 2009 May 28; 360:2289 Levine RL and Carroll M., N Engl J Med 2009 May 28; 360:2355

SUMMARY AND COMMENT

Biopsies of New Metastatic Lesions in Breast Cancer

• May 26, 2009
• William J. Gradishar, MD

Knowledge of discordance in molecular markers between primary tumors and metastatic lesions altered disease management in 20% of patients.

• Reviewing:
• Simmons C et al., Ann Oncol 2009 Mar 18

SUMMARY AND COMMENT

Brain Metastases in Triple-Negative Breast Cancer

• May 26, 2009
• William J. Gradishar, MD

Cumulative incidence at 5 years was nearly 10%.

• Reviewing:
• Dawood S et al., Ann Oncol 2009 Apr; 20:621

SUMMARY AND COMMENT

Tumor Suppression in Diffuse Large B-Cell Lymphoma

• May 26, 2009
• Michael E. Williams, MD

Mutations in regulatory genes for nuclear factor kappa beta offer potential therapeutic targets.

• Reviewing:
• Compagno M et al., Nature 2009 May 3

SUMMARY AND COMMENT

Chemotherapy Resistance in Chronic Lymphocytic Leukemia

• May 19, 2009
• Michael E. Williams, MD

MicroRNA-expression abnormalities were associated with resistance to fludarabine.

• Reviewing:
• Zenz T et al., Blood 2009 Apr 16; 113:3801

SUMMARY AND COMMENT

Preoperative Chemoradiotherapy for Esophageal Cancer

• May 19, 2009
• David H. Ilson, MD, PhD

Combined preoperative chemotherapy and radiotherapy seemed to confer greater benefit than preoperative chemotherapy alone.

• Reviewing:
• Stahl M et al., J Clin Oncol 2009 Feb 20; 27:851

SUMMARY AND COMMENT

Cetuximab for KRAS Wild-Type Colorectal Cancer

• May 19, 2009
• David H. Ilson, MD, PhD

First-line treatment with cetuximab was associated with benefits for progression-free survival and antitumor response, but not overall survival.

• Reviewing:
• Van Cutsem E et al., N Engl J Med 2009 Apr 2; 360:1408

SUMMARY AND COMMENT

Optimal Duration of Anticoagulation for Venous Thromboembolism

• May 19, 2009
• David Green, MD, PhD

Using ultrasonography data to guide duration of therapy helped lower rates of recurrent VTE.

• Reviewing:
• Prandoni P et al., Ann Intern Med 2009 May 5; 150:577

SUMMARY AND COMMENT

Adjuvant Chemotherapy in Older Patients with Breast CancerFree

• May 13, 2009
• William J. Gradishar, MD

Capecitabine was inferior to standard chemotherapy.

• Reviewing:
• Muss HB et al., N Engl J Med 2009 May 14; 360:2055

SUMMARY AND COMMENT

Venous Thromboembolism in Patients with Acute Leukemia

• May 12, 2009
• David Green, MD, PhD

VTE incidence was similar to that in patients with other forms of cancer.

• Reviewing:
• Ku GH et al., Blood 2009 Apr 23; 113:3911